Bristol Myers Squibb stock gains pediatric Camzyos evidence

Bristol Myers Squibb presented extended clinical evidence for Camzyos on November 6, 2026, at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions in Chicago. The company's investor release covered 56-week results from the Phase 3 SCOUT-HCM trial of Camzyos, or mavacamten, in adolescents with symptomatic obstructive hypertrophic cardiomyopathy.

Bristol Myers Squibb stock traded at 55.83 euros on Lang & Schwarz at 12:56 CET on Wednesday, November 11, 2026. The quote provides the current trading reference for investors as the market assesses the company's expanding cardiovascular franchise.

Longer Follow-up Supports Camzyos

SCOUT-HCM enrolled 44 patients aged 12 to less than 18 years. Of those participants, 43 completed the initial 28-week double-blind, placebo-controlled period and entered active treatment. Patients who initially received placebo switched to Camzyos at week 28, allowing the study to extend treatment observations through week 56.

Patients who received mavacamten throughout the study recorded a mean change from baseline of minus 48.1 mmHg in the Valsalva left ventricular outflow tract gradient after 56 weeks. The group that switched from placebo also achieved a similar reduction after starting active treatment. Bristol Myers Squibb said both study arms showed meaningful improvements in several secondary endpoints.

The findings were consistent with the earlier 28-week results and added duration to the evidence supporting Camzyos in younger patients. The company said no new safety signals emerged. In the continuous-treatment arm, five treatment-related treatment-emergent adverse events and two serious treatment-emergent adverse events were reported over 56 weeks. The placebo-to-Camzyos arm recorded one treatment-related event and no serious event during its 28-week active-treatment period.

FDA Approval Opens Pediatric Market

The U.S. Food and Drug Administration approved Camzyos in September 2026 for pediatric patients weighing at least 30 kilograms with symptomatic obstructive hypertrophic cardiomyopathy. That decision followed the positive 28-week SCOUT-HCM results. The product had previously been approved in the United States for adults with symptomatic New York Heart Association class II-III obstructive hypertrophic cardiomyopathy.

The 56-week update therefore supports an indication that has only recently expanded beyond adults. For Bristol Myers Squibb, longer follow-up can help physicians assess treatment durability while the pediatric launch develops. Commercial adoption will still depend on prescribing, monitoring and the restricted Camzyos Risk Evaluation and Mitigation Strategy program.

The study's safety observation was notable because no patient experienced a left ventricular ejection fraction below 50 percent during the 56-week period. Camzyos carries a boxed warning for heart failure caused by systolic dysfunction, and the prescribing information requires echocardiogram assessments before and during treatment. The safety finding supports continued evaluation but does not remove the need for monitoring.

Long-Term Trial Work Continues

SCOUT-HCM includes a long-term extension of up to 144 weeks after the placebo-controlled and active-treatment periods, giving Bristol Myers Squibb an opportunity to build a larger follow-up record in adolescents. The company also presented additional adult Camzyos analyses at the American Heart Association's Scientific Sessions, including four-year REMS findings and cardiac imaging follow-up of up to five years.

The Bristol Myers Squibb stock remains linked to the company's ability to convert clinical progress into durable cardiovascular revenue while managing safety requirements and development risk.

The U.S. pharmaceutical market remains the relevant broader setting for Bristol Myers Squibb, alongside the S&P 500.

More news and analyses on Bristol Myers Squibb stock.

Bristol Myers Squibb at a Glance

• Company: Bristol Myers Squibb
• ISIN: US1101221083
• Ticker: BMY
• Home exchange: New York Stock Exchange
• Lang & Schwarz quote: 55.83 euros on Wednesday, November 11, 2026, at 12:56 CET
• Clinical program: Phase 3 SCOUT-HCM
• Product: Camzyos (mavacamten)